In a patient with an HbA1c of 5.8% who is taking glimepiride (a sulfonylurea), should the medication be discontinued?

Yes, glimepiride should be discontinued or dose-reduced in a patient with an HbA1c of 5.8%

Clinicians should deintensify pharmacologic therapy in patients with type 2 diabetes who achieve HbA1c levels less than 6.5%, particularly when using medications that cause hypoglycemia such as sulfonylureas. 1

Rationale for Discontinuation

An HbA1c of 5.8% is substantially below the standard glycemic target of 7.0% and well below the 6.5% threshold that triggers deintensification recommendations. The evidence is clear on this point:

• No clinical benefit exists for HbA1c targets below 6.5% - The ACCORD trial, which targeted HbA1c <6.5% and achieved 6.4%, was stopped early due to increased overall mortality and cardiovascular deaths 1
• Substantial harm from over-treatment - Maintaining such low HbA1c levels with sulfonylureas significantly increases hypoglycemia risk, which can cause serious morbidity including falls, cardiovascular events, and cognitive impairment 1
• Glimepiride specifically carries hypoglycemia risk - As a sulfonylurea, glimepiride stimulates insulin secretion regardless of glucose levels, creating persistent hypoglycemia risk 2

Deintensification Strategy

The 2022 ADA/EASD consensus explicitly states: "HbA1c levels below 48 mmol/mol (6.5%) or substantially below the individualised glycaemic target as well as any increased risk of hypoglycaemia should prompt stopping or reducing the dose of medications associated with an increased risk of hypoglycaemia." 3

Recommended approach:

1. Discontinue glimepiride entirely if the patient is on multiple glucose-lowering agents
2. Reduce to the lowest effective dose if glimepiride is the only or primary agent and you want to maintain some glycemic control
3. Monitor closely - Check HbA1c in 3 months to ensure levels remain <7.0% but ideally stay above 6.5%

Important Caveats

If the patient is also on metformin: The evidence suggests metformin can be continued even at low HbA1c levels since it doesn't cause hypoglycemia, is weight-neutral, and provides cardiovascular benefits 1. However, glimepiride should still be stopped.

Hypoglycemia risk is the priority concern: The 2018 ACP guidance emphasizes that "if a patient achieves an HbA1c level less than 6.5%, the clinician should deintensify treatment by reducing the dosage, removing a medication if the patient is receiving more than 1, or discontinuing pharmacologic treatment" 1. This is particularly critical for sulfonylureas.

Timing considerations: If the patient recently took their daily glimepiride dose, they should be instructed to eat foods to prevent hypoglycemia until the medication effect wears off (approximately 12-24 hours) 4. The FDA label confirms glimepiride's prolonged duration of action 2.

Clinical Outcome Priorities

This recommendation prioritizes mortality and morbidity reduction over tight glycemic control. The ACCORD and ADVANCE trials demonstrated that targeting HbA1c below 6.5% increases death rates without providing additional microvascular or macrovascular benefits 1. At 5.8%, this patient is in a dangerous zone where treatment harm clearly outweighs any theoretical benefit.

The risk-benefit calculation is unequivocal: discontinue the glimepiride.